AstraZeneca Pharma India (506820) Q4 25/26 earnings summary

Executive summary

• Achieved 33% year-over-year growth in total revenue, reaching INR 22,755.8 million for FY 2025-26, driven by strong performance in Oncology, Biopharmaceuticals, and Rare Disease segments.

• Secured 11 new regulatory approvals for medicines and indications, reinforcing leadership in key therapy areas and accelerating delivery of innovative medicines in India.

• Recognized with multiple industry awards, including Pharma Company of the Year and Medical Excellence Award for Rare Disease.

Financial highlights

• Total revenue from operations for FY 2025-26 was INR 22,755.8 million, up from INR 17,162.9 million in FY 2024-25.

• Profit before exceptional items and tax for FY 2025-26 was INR 2,574.5 million, compared to INR 2,531.5 million in the prior year.

• Profit after tax for FY 2025-26 was INR 1,875.2 million, up from INR 1,157.4 million year-over-year.

• Earnings per share (basic and diluted) for FY 2025-26 stood at INR 75.01, compared to INR 46.30 in FY 2024-25.

• Cash and cash equivalents at year-end were INR 4,477.2 million, down from INR 5,361.4 million at the end of the previous year.

Outlook and guidance

• Management remains focused on advancing a strong pipeline, addressing unmet medical needs, and creating long-term impact through science-led innovation.

• Continued emphasis on expanding patient access and accelerating delivery of innovative therapies in India.